Researchers at La Jolla Institute for Immunology (LJI) have found that T cells from people who have recovered from COVID-19 or received the Moderna or Pfizer-BioNTech vaccines are still able to recognize several concerning SARS-CoV-2 variants.
Researchers at La Jolla Institute for Immunology (LJI) have shed light on a process in immune cells that may explain why some people develop cardiovascular diseases. Their research, published recently in Genome Biology, shows the key role that TET enzymes play in keeping immune cells on a healthy track as they mature. The scientists found that other enzymes do play a role in this process—but TET enzymes do the heavy lifting.
New research led by scientists at La Jolla Institute for Immunology (LJI) and the University of Liverpool may explain why many cancer patients do not respond to anti-PD-1 cancer immunotherapies—also called checkpoint inhibitors. The team reports that these patients may have tumors with high numbers of T follicular regulatory (Tfr) cells.
The National Cancer Institute (NCI) of the National Institutes of Health has granted over $4.2 million to launch the Cancer Epitope Database and Analysis Resource (CEDAR), led by La Jolla Institute for Immunology (LJI) Professors Alessandro Sette, Dr. Biol. Sci., and Bjoern Peters, Ph.D.
The La Jolla Institute for Immunology (LJI) is partnering with Synbal, Inc., a preclinical biotechnology company based in San Diego, CA, to develop multi-gene, humanized mouse models for COVID-19 research. The research at LJI will be led by Professor Sujan Shresta, Ph.D., a member of the Institute’s Center for Infectious Disease and Vaccine Research.
In a new paper, scientists from La Jolla Institute for Immunology (LJI) bring together research findings from COVID-19 researchers around the world. The results are striking: human T cells can target more than 1,400 sites on the SARS-CoV-2 virus.
In a new Cell Reports study, researchers at La Jolla Institute for Immunology demonstrate how Ebola virus has found a different way to get things done. The virus encodes only eight proteins but requires dozens of functions in its lifecycle. The new study shows how one of Ebola virus’s key proteins, VP40, uses molecular triggers in the human cell to transform itself into different tools for different jobs.
Viruses churn out genetic material in parts of the cell where it's not supposed to be. Cancer cells do too. A new study shows that a tumor-suppressor enzyme called DAPK3 is an essential component of a multi-protein system that senses misplaced genetic material in tumor cells, and slows tumor growth by activating the fierce-sounding STING pathway.
Erica Ollmann Saphire, Ph.D., has been appointed President and CEO of La Jolla Institute for Immunology (LJI), the Institute announced today. Dr. Saphire will become La Jolla Institute’s fifth president when she formally begins her term on September 1, 2021. She will succeed current LJI President Mitchell Kronenberg, who has successfully led the organization for the past 18 years.
Translational research led by scientists at La Jolla Institute for Immunology (LJI) has resulted in a promising combination therapeutic candidate for adults with recent-onset type 1 diabetes.
La Jolla Institute for Immunology (LJI), one of the leading research organizations dedicated to studying the immune system announced today that it has signed a licensing agreement with Leinco Technologies, Inc., a premier developer and manufacturer of leading-edge recombinant proteins, antibodies, and conjugates.
A new study led by scientists at La Jolla Institute for Immunology (LJI) suggests that T cells try to fight SARS-CoV-2 by targeting a broad range of sites on the virus—beyond the key sites on the virus's spike protein. By attacking the virus from many angles, the body has the tools to potentially recognize different SARS-CoV-2 variants.
A big question on people's minds these days: how long does immunity to SARS-CoV-2 last following infection? Now a research team from La Jolla Institute for Immunology (LJI), The University of Liverpool and the University of Southampton has uncovered an interesting clue. Their new study suggests that people with severe COVID-19 cases may be left with more of the protective "memory" T cells needed to fight reinfection.
The findings, based on analyses of blood samples from 188 COVID-19 patients, suggest that responses to the novel coronavirus, SARS-CoV-2, from all major players in the "adaptive" immune system, which learns to fight specific pathogens, can last for at least eight months after the onset of symptoms from the initial infection.
The COVID-19 pandemic has highlighted how our small genetic differences can have a tremendous effect on how our bodies respond to disease. Researchers have created 3D maps of how enhancer sequences and genes interact in several types of immune cells. Their new study opens the door to understanding individual risk for diseases from asthma to cancer.
Researchers at La Jolla Institute for Immunology (LJI) have found that people with sepsis have never-before-seen particles in their blood. The scientists are the first to show that these particles, called elongated neutrophil-derived structures (ENDS), break off of immune cells and change their shape as they course through the body.
While quick-acting inhalers and medications can reduce inflammation during an asthma attack, people with asthma have few tools to prevent the next attack from coming. Now researchers at La Jolla Institute for Immunology (LJI) have discovered that blocking two immune molecules at the same time is key to preventing asthma attacks in a mouse model.
In a new Science Advances study, Shresta and her colleagues at LJI report that the immune system's T cells have the power to prevent Zika infection in mice. This finding suggests that effective Zika vaccines need to activate T cells to work alongside antibodies.
It's long been thought that having "autoreactive" T cells in the pancreas was a sure sign of type 1 diabetes. Yet a new study led by scientists at La Jolla Institute for Immunology (LJI) shows that even healthy people have these cells lurking in the pancreas—in surprisingly high numbers.
A new international study led by scientists at La Jolla Institute for Immunology (LJI), The University of Liverpool and the University of Southampton is the first to give a detailed snapshot of how the body's CD4+ T cells respond to the SARS-CoV-2 virus. Among the findings, their work suggests that early in the illness, patients hospitalized with severe cases of COVID-19 develop a novel T cell subset that can potentially kill B cells and reduce antibody production.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right